RPG LIFESCIENCES LTD - QUARTERLY RESULTS - FOR Q4 FY 2013 - GOOD IMPROVEMNT - FUTURE APPEALING

RPG LIFESCIENCES LTD

RESULTS FOR Q4 FY 2013

RPG LIFESCIENCES LTD has performed well in Q4 FY 2013 compared to the preceding and corresponding Quarters.

Net Sales for Q4 FY 13 stands at Rs.56.34 Cr; compared to Rs.48.09 cr in the preceding Qtr of Q3 FY 13 ( + 17.16% ); and compared to Rs.41.23 cr in the corresponding quarter of Q4 FY 13 (+36.65%). Net Sales has improved reasonably well in Q4.

Total Expenditure for Q4 FY 13 stands at Rs.53.72 Cr; compared to Rs.53.88 cr in the preceding Qtr of Q3 FY 13 ( -0.3% ); and compared to Rs.47.45 cr in the corresponding quarter of Q4 FY 13 (+13.21%). Total expenditure has gone up less than proportionately compared to Net Sales.

Total Income     for Q4 FY 13 stands at Rs.58.41 Cr; compared to Rs.49.01 cr in the preceding Qtr of Q3 FY 13 ( +19.18% ); and compared to Rs.42.20 cr in the corresponding quarter of Q4 FY 13 (+38.41%). Total Income has gone up impressively both QoQ and YoY.

Cost of materials  for Q4 FY 13 stands at Rs.12.12 Cr; compared to Rs.13.59 cr in the preceding Qtr of Q3 FY 13 ( -10.82% ); and compared to Rs.9.31cr in the corresponding quarter of Q4 FY 13 (+30.18%). Cost of Materials has gone up significantly, though less than proportionately with the Net Sales.

Purchases of SIT for Q4 FY 13 stands at Rs.4.25 Cr; compared to Rs.4.11 cr in the preceding Qtr of Q3 FY 13 ( +3.41% ); and compared to Rs.3.54 cr in the corresponding quarter of Q4 FY 13 (+20.06%).

Employee benefits          for Q4 FY 13 stands at Rs.13.51 Cr; compared to Rs.13.91 cr in the preceding Qtr of Q3 FY 13 ( -2.88% ); and compared to Rs.12.24 cr in the corresponding quarter of Q4 FY 13 (+10.38%).

Depreciation      for Q4 FY 13 stands at Rs.2.53 Cr; compared to Rs.2.57 cr in the preceding Qtr of Q3 FY 13 ( -1.56% ); and compared to Rs.2.60  cr in the corresponding quarter of Q4 FY 13 (-2.69%).

Other expenses for Q4 FY 13 stands at Rs.16.90 Cr; compared to Rs.19.30 cr in the preceding Qtr of Q3 FY 13 ( -12.44% ); and compared to Rs.17.82cr in the corresponding quarter of Q4 FY 13 (-5.16%).

Total expenses  for Q4 FY 13 stands at Rs.53.72 Cr; compared to Rs.53.88 cr in the preceding Qtr of Q3 FY 13 ( -0.3% ); and compared to Rs.47.45cr in the corresponding quarter of Q4 FY 13 (+13.21%). Expenses are thus under reasonable control.

Profit before tax              for Q4 FY 13 stands at Rs.3.53 Cr; compared to Rs.(-)6.35 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)6.43 cr in the corresponding quarter of Q4 FY 13. At the PBT stage also, the improvement is significant.

Tax Expenses     for Q4 FY 13 stands at Rs.(-)3.87 Cr; compared to Rs.(-)0.26 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)0.74cr in the corresponding quarter of Q4 FY 13. The lower Tax expenses has significantly enhance the net Profits.

Net Profit            for Q4 FY 13 stands at Rs.7.40 Cr; compared to Rs.(-)6.09 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)5.69cr in the corresponding quarter of Q4 FY 13. Net Profit has improved decisively and significantly in the 4^th quarter.

Face Value of Share is Rs.8.

Paid-up Equity stands at Rs.13.23 Cr.

Basic EPS for Q4 FY 13 stands at Rs.4.48; compared to Rs(-)3.68 in the preceding quarter and Rs.(-)3.44 in the corresponding quarter. This is a significant improvement over both the preceding and corresponding quarters.

Public holding in the company stands at 43.52%.

The improvement in the performance of RPG Lifesciences in Q4 is very good. RPGLIF is acquiring more and more approvals for its products and for its factories, which is good for its long term performance.

 *  *  *  E  N  D  *  *  *